NCT06762808View on ClinicalTrials.gov

Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 1, 2025

Primary Completion Date

August 8, 2025

Study Completion Date

August 8, 2025

Conditions
Squamous Cell Carcinoma
Interventions
DRUG

Atezolizumab

Given by IV infusion

DRUG

Talazoparib

Given by IV infusion

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Strategic Alliance

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER